Explore every episode of the podcast PETRI DISH PERSPECTIVES
| Title | Pub. Date | Duration | |
|---|---|---|---|
| Episode 71: Fate of Pharma M&A | 03 Sep 2026 | 00:22:24 | |
In this episode of Petri Dish Perspectives, we take a step back from individual companies to examine one of the most powerful forces shaping the pharmaceutical industry: M&A, licensing, and the global competition for innovation. We explore how today's pharmaceutical giants were built through decades of consolidation, from Pfizer, GlaxoSmithKline, and Novartis to some of the industry's biggest modern transactions and why dealmaking has increasingly become essential for companies facing massive patent cliffs. But modern pharma is changing. Instead of relying solely on internal R&D or pursuing enormous megamergers, companies are increasingly acquiring targeted biotechs, licensing individual assets, and looking outside traditional innovation hubs for their next blockbuster. We'll also dive into one of the biggest shifts happening in biotech today: the rise of China and Asia as sources of innovative drug development. Western pharmaceutical companies are increasingly licensing molecules and technologies developed outside the U.S. and Europe, even as governments push for supply-chain independence and greater scrutiny of strategic relationships with China. What happens when the pharmaceutical industry is becoming more global while geopolitics is becoming less global? From the biggest deals in pharmaceutical history to the future of cross-border biotech partnerships, this episode asks a bigger question: Has Big Pharma become too dependent on buying innovation rather than building it? And if the best science can increasingly come from anywhere in the world, who will ultimately control the future of medicine? Because pharmaceutical M&A isn't just about buying companies. It's about deciding who gets to own the future of medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #Pharma #Biotech #PharmaMA #BiotechMA #DrugDevelopment #BigPharma #PharmaceuticalIndustry #BiotechInnovation #Healthcare #LifeSciences #BusinessDevelopment #Licensing #PatentCliff #ChinaBiotech #GlobalHealth #Geopolitics #DrugDiscovery #Innovation #HealthcareInnovation © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| August 2026: Biotech & Pharma NEWS Roundup | 01 Sep 2026 | 00:11:29 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for August 2026! This month was defined by major dealmaking, a resurgence in biotech financing, and growing questions about where the global biotech industry is headed. Roche made a $2.5 billion bet on Hanmi, McKesson acquired Precision Medicine Group for $2.25 billion, and the investors behind Metsera quickly returned with Sentivera and a licensing deal worth up to $1.5 billion. Meanwhile, companies including Apnimed, Attovia, and Braveheart kept the IPO market active, suggesting that investor appetite for biotech may be continuing to recover. On the regulatory front, a series of FDA approvals expanded treatment options across HIV, autoimmune disease, cardiovascular disease, cancer, and rare disorders, while three reported deaths in Chinese gene therapy trials sparked renewed debate in Washington about clinical-trial oversight and the FDA's reliance on international data. The bigger story is clear: biotech is becoming increasingly global, capital-intensive, and interconnected, where success depends not only on great science, but also on manufacturing, financing, regulation, and strategic partnerships. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 70: Cellares | 27 Aug 2026 | 00:21:43 | |
In this episode of Petri Dish Perspectives, we explore Cellares, the biotech company trying to solve one of the biggest and least discussed challenges in cell therapy: how do you manufacture these complex, personalized medicines at commercial scale? From CAR-T to gene-edited cell therapies, the science may be advancing rapidly, but manufacturing remains labor-intensive, expensive, and difficult to scale. Cellares believes the answer is automation. We’ll break down the origins of Cellares, the engineering philosophy behind its Cell Shuttle platform, and how the company is attempting to turn cell therapy manufacturing into something closer to an automated pharmaceutical factory. We’ll also explore its partnerships with companies including Bristol Myers Squibb and Cabaletta Bio, the massive investment behind its Smart Factory network, and why pharmaceutical companies have become increasingly interested in automating cell therapy production. But there’s a major twist: Bristol Myers Squibb recently terminated its partnership with Cellares, raising questions about whether the Cell Shuttle is truly ready for commercial-scale manufacturing. We’ll unpack what happened, why manufacturing a clinical-stage therapy isn't necessarily the same as manufacturing a commercial product, and what this could mean for Cellares and the broader future of automated cell therapy. Because the next breakthrough in cell therapy may not be another drug, it may be the factory that finally makes these living medicines scalable. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Cellares #CellTherapy #CAR_T #CAR-T #Biotech #Biotechnology #Pharma #CellTherapyManufacturing #Biomanufacturing #GeneTherapy #DrugDevelopment #LifeSciences #Healthcare #BristolMyersSquibb #CabalettaBio #CellShuttle #Manufacturing #BiotechInnovation #PrecisionMedicine © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 69: Summit Therapeutics | 20 Aug 2026 | 00:21:51 | |
In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda. We’ll dive into Summit’s origins, the company’s dramatic pivot, the story behind its partnership with China’s Akeso, and the science behind why combining immune checkpoint inhibition with VEGF blockade could create a powerful new approach to cancer treatment. We’ll also break down the clinical data in lung cancer, Summit’s growing pipeline, the massive commercial opportunity, and the risks surrounding regulatory approval, clinical durability, and the company’s heavy dependence on a single lead asset. But Summit’s story goes far beyond one cancer drug. Ivonescimab represents a broader shift in how medicines are discovered and commercialized, with innovative assets increasingly emerging from Chinese biotech and being licensed by Western companies for global development. Could Summit become the company that brings a new generation of cancer therapeutics to the world and could ivonescimab really become a challenger to Keytruda? 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #SummitTherapeutics #Ivonescimab #Biotech #Biotechnology #Pharma #Oncology #Cancer #CancerResearch #Immunotherapy #BispecificAntibodies #PrecisionMedicine #DrugDevelopment #ClinicalTrials #Keytruda #Merck #ChineseBiotech #Healthcare #LifeSciences #PharmaceuticalIndustry © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 68: Guardant Health | 13 Aug 2026 | 00:23:24 | |
In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic scientists Helmy Eltoukhy and AmirAli Talasaz, Guardant is betting that a simple blood draw can reveal critical information about the biology of a tumor, from identifying mutations and guiding treatment to monitoring residual disease and potentially detecting cancer earlier. We'll dive into the science behind liquid biopsy and circulating tumor DNA, Guardant's evolution from Guardant360 into a broader precision-oncology platform, the rise of its Shield colorectal cancer screening test, and the company's growing role in pharmaceutical drug development, real-world evidence, and AI. We'll also explore the promise and major challenges of multi-cancer early detection, including the questions around sensitivity, false positives, reimbursement, and whether detecting cancer earlier actually translates into better outcomes. Because the future of cancer care may not just be about developing better treatments, but about being able to continuously read what cancer is doing inside the body from something as simple as a blood sample. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #GuardantHealth #LiquidBiopsy #Cancer #Oncology #Biotech #Healthcare #PrecisionMedicine #CancerDetection #Genomics #ctDNA #Diagnostics #HealthTech #Pharma #AI #Biotechnology #FutureOfHealthcare © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 67: Epic Systems | 06 Aug 2026 | 00:23:08 | |
In this episode of Petri Dish Perspectives, we explore the story of Epic Systems, the privately held healthcare technology company that has quietly built much of the digital infrastructure behind American healthcare. From Judy Faulkner founding Epic in a Wisconsin basement to becoming the dominant electronic health record platform, Epic has transformed how hospitals, physicians, and patients interact with medical information. We'll dive into Epic's founding story, the evolution of its electronic health record, the rise of MyChart and Cosmos, and how Epic built a massive competitive moat through interoperability, data, workflow integration, and switching costs. We'll also explore its growing role in artificial intelligence, how Epic is embedding AI directly into clinical workflows, and the battle with companies like Oracle Health to control the future of healthcare data. Because the next generation of healthcare won't just be about developing better drugs and devices, it will be about who controls the information infrastructure connecting patients, providers, data, and AI. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #EpicSystems #Healthcare #HealthTech #Biotech #Pharma #AI #ArtificialIntelligence #DigitalHealth #HealthcareInnovation #JudyFaulkner #EHR #HealthData #MedTech #FutureOfHealthcare © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| July 2026: Biotech & Pharma NEWS Roundup | 01 Aug 2026 | 00:09:27 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships spanning Anthropic, NVIDIA, Insilico Medicine, and major pharmaceutical companies. At the same time, billion-dollar licensing deals and acquisitions showed that large pharma is aggressively buying innovation rather than building everything internally, particularly in obesity, oncology, radiopharmaceuticals, and gene editing. Regulatory headlines—from the FTC's lawsuit against Hims & Hers to renewed debates around animal testing—reminded us that policy is evolving just as quickly as the science. And with companies like Apnimed and Scribe Therapeutics successfully entering the public markets, investor confidence appears to be returning to biotech. The takeaway is clear: the future of healthcare will be shaped by the convergence of biology, artificial intelligence, precision medicine, and strategic dealmaking—and this month may be remembered as another major step toward that future. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 66: Scribe Therapeutics | 30 Jul 2026 | 00:23:51 | |
In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than accepting the size, delivery, and precision limitations of traditional Cas9, Scribe is redesigning the molecular machinery itself, building smaller, faster, and more versatile X-Editors and pioneering the future of epigenetic regulation. We'll dive into the origins of CRISPR from bacterial immune systems to Nobel-winning breakthroughs, the protein engineering philosophy of co-founder Jennifer Doudna and Benjamin Oakes, and why pharmaceutical giants like Biogen, Eli Lilly, and Sanofi have poured resources into its platform. We'll also break down its pipeline targeting cardiometabolic diseases, rare genetic disorders, and the promise of reversible gene silencing. Because the next era of genetic medicine won't just belong to those who discover biology, but to those who engineer it into safer, more precise cures. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ScribeTherapeutics #Biotech #CRISPR #GeneEditing #ProteinEngineering #Genomics #Genetics #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Cardiometabolic #Epigenetics #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 65: Apogee Therapeutics | 23 Jul 2026 | 00:23:29 | |
In this episode of Petri Dish Perspectives, we explore the story of Apogee Therapeutics, one of biotech's newest immunology companies aiming to redefine autoimmune disease through next-generation antibody engineering. Rather than chasing entirely new biological targets, Apogee is focused on improving what already works, developing longer-lasting biologics that could reduce injections from every few weeks to every few months. We'll dive into the evolution of modern immunology, the science behind cytokines and Fc engineering, how Apogee emerged from biotech incubator Paragon Therapeutics, and why investors have poured hundreds of millions of dollars into its vision. We'll also break down its pipeline, including APG777, APG808, and other promising candidates targeting eczema, asthma, inflammatory bowel disease, and beyond. Because sometimes the biggest innovation isn't discovering new biology, it's engineering better medicines for the patients who depend on them. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ApogeeTherapeutics #Biotech #Immunology #AutoimmuneDisease #Biologics #AntibodyEngineering #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Dermatology #Asthma #Inflammation #ProteinEngineering #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 64: Conception Bio | 16 Jul 2026 | 00:23:16 | |
In this episode of Petri Dish Perspectives, we explore the story of Conception Bio, one of the most ambitious biotechnology companies working at the intersection of stem cell biology, reproductive medicine, and regenerative science. Their mission? To make eggs from ordinary cells through in vitro gametogenesis (IVG), a breakthrough that could fundamentally change how we think about infertility, fertility preservation, and human reproduction. We'll dive into the science behind IVG, the pioneering research that made the field possible, the founders' vision, and why investors believe reproductive biology could become one of biotech's next major frontiers. We'll also discuss the enormous technical hurdles, ethical questions, and potential applications for cancer survivors, age-related infertility, LGBTQ+ family building, and beyond. Because the next revolution in medicine may not be about curing disease, it may be about creating life's very first cell. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ConceptionBio #Fertility #IVF #StemCells #RegenerativeMedicine #Biotech #ReproductiveBiology #InVitroGametogenesis #IVG #DrugDiscovery #Healthcare #LifeSciences #DevelopmentalBiology #PrecisionMedicine #WomenInScience #Biotechnology #SciencePodcast #FutureOfMedicine #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 63: Enveda Biosciences | 09 Jul 2026 | 00:23:47 | |
In this episode of Petri Dish Perspectives, we explore the story of Enveda Biosciences, one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most pharmaceutical companies build vast synthetic chemical libraries, Enveda is using artificial intelligence, metabolomics, and mass spectrometry to unlock the world's largest and largely untapped chemical library: nature. We'll trace the history of natural product drug discovery, from penicillin and paclitaxel to the AI revolution, dive into founder Viswa Colluru's vision of creating a searchable map of nature's chemistry, and explore how Enveda's platform is transforming plants, fungi, and microbes into tomorrow's medicines. We'll also discuss the company's growing clinical pipeline, why investors have poured hundreds of millions into the platform, and whether AI can finally solve one of drug discovery's oldest challenges. Because sometimes, the future of medicine isn't invented, it evolves. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Enveda #ArtificialIntelligence #AI #DrugDiscovery #Biotech #NaturalProducts #MachineLearning #Metabolomics #Pharmaceuticals #Healthcare #PrecisionMedicine #MedicinalChemistry #LifeSciences #Biotechnology #Innovation #ClinicalResearch #DrugDevelopment #SciencePodcast #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 62: Isomorphic Labs | 02 Jul 2026 | 00:24:09 | |
In this episode of Petri Dish Perspectives, we explore the story of Isomorphic Labs, Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one of biology's greatest mysteries, protein folding, to building an AI-native pharmaceutical company, Isomorphic Labs is attempting to fundamentally change how medicines are discovered. We'll dive into the origins of AlphaFold, the scientific vision of Nobel Prize-winning CEO Demis Hassabis, how AI is reshaping medicinal chemistry, and why pharmaceutical giants like Novartis and Eli Lilly are investing billions in AI-powered drug discovery partnerships. We'll also discuss the promise, challenges, and future of foundation models in biology, and whether AI can truly accelerate the journey from molecule to medicine. Because the next blockbuster drug may not be discovered by chance, it may be designed by an algorithm. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #IsomorphicLabs #DeepMind #AlphaFold #ArtificialIntelligence #AI #DrugDiscovery #Biotech #Healthcare #PrecisionMedicine #Pharmaceuticals #MachineLearning #ProteinFolding #DemisHassabis #NobelPrize #MedicinalChemistry #LifeSciences #Biology #Google #Alphabet #EliLilly #Novartis #FutureOfMedicine #SciencePodcast #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| June 2026: Biotech & Pharma NEWS Roundup | 30 Jun 2026 | 00:10:00 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped capital for late-stage security while doubling down on early-stage, high-tech innovation. From AbbVie’s multi-billion-dollar immunology power play to a flurry of high-stakes partnerships involving AI-native drug discovery and novel protein-degradation platforms, the industry spent June 2026 signaling a clear preference for integrated precision, prioritizing assets that can bypass traditional resistance mechanisms and redefine standards of care in oncology and metabolic disease. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 61: Danaher | 25 Jun 2026 | 00:23:54 | |
In this episode of Petri Dish Perspectives, we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive into the origins of the Danaher Business System (DBS), the acquisition strategy that reshaped biotechnology, the landmark purchases of Beckman Coulter, Pall, and Cytiva, and why Danaher became one of the biggest winners of the COVID-19 era. While biotech headlines focus on breakthrough drugs and billion-dollar acquisitions, Danaher quietly supplies the tools, diagnostics, manufacturing systems, and technologies that power modern medicine. From sequencing cancer genomes and producing monoclonal antibodies to manufacturing gene therapies and vaccines, Danaher sits behind the scenes enabling scientific innovation across the globe. We'll also discuss the leadership of Larry Culp, the company's role in the rise of biologics, gene therapies, and precision medicine, and the lessons Danaher offers about building value through infrastructure rather than blockbuster products. Because sometimes the companies changing healthcare aren't the ones discovering the drugs, they're the ones making discovery possible. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Danaher #Biotech #LifeSciences #Healthcare #Biopharma #Cytiva #PallCorporation #BeckmanCoulter #Diagnostics #GeneTherapy #CellTherapy #Biologics #Pharmaceuticals #DrugDevelopment #PrecisionMedicine #LaboratoryScience #LarryCulp #BusinessPodcast #BiotechPodcast #HealthcareInnovation #Investing #Science #CorporateHistory #HealthcareBusiness © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 60: Hims & Hers | 18 Jun 2026 | 00:25:55 | |
In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscription medicine, and aggressive branding to reach millions of patients. We explore the company's founding story, rapid growth, SPAC-era public debut, expansion into mental health, dermatology, weight loss, and primary care, as well as the controversies surrounding compounded GLP-1 medications, regulatory scrutiny, and the broader debate around the future of telemedicine. From Silicon Valley startup to healthcare disruptor, Hims & Hers offers a fascinating case study in consumerization, accessibility, and the changing relationship between patients and providers. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #HimsAndHers #Telehealth #DigitalHealth #HealthcareInnovation #GLP1 #WeightLossDrugs #Biotech #HealthcareBusiness #StartupStories #PublicMarkets #HealthcareTechnology #DirectToConsumer #Pharma #HealthTech #BusinessPodcast #AndrewDudum #Medicine #HealthcareDisruption #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 59: Illumina | 11 Jun 2026 | 00:23:27 | |
In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale genetic studies. You'll hear how the company built an empire around the idea that reading DNA would become as essential to medicine as blood tests and imaging scans. We also unpack the major milestones that shaped Illumina's rise: the acquisition of Solexa, the launch of revolutionary sequencing platforms, the race to the "$1,000 genome," and the company's ambitious vision for detecting cancer through blood tests. Along the way, we'll examine the controversial Grail acquisition, regulatory battles with the European Union, leadership shakeups, and the strategic decisions that defined one of biotech's most influential companies. From the Human Genome Project to multi-billion-dollar cancer screening ambitions, this is the story of the company that made genomics mainstream. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Illumina #Genomics #DNASequencing #HumanGenomeProject #Grail #CancerDetection #LiquidBiopsy #Biotech #Biotechnology #PrecisionMedicine #GeneticTesting #NextGenerationSequencing #NGS #LifeSciences #HealthcareInnovation #MolecularBiology #CancerResearch #BioTechPodcast #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 58: UnitedHealthcare | 04 Jun 2026 | 00:23:59 | |
In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hundreds of billions of dollars, UnitedHealthcare has fundamentally transformed how healthcare is financed, delivered, and managed in the United States. We explore the company's founding story, the leadership of industry-defining executives, the creation of Optum, and the acquisition strategy that turned UnitedHealth into far more than an insurance company. We also unpack the controversies surrounding prior authorizations, claim denials, Medicare Advantage investigations, antitrust concerns, and the growing public frustration with the American healthcare system. Finally, we examine one of the most shocking moments in modern corporate history: the assassination of CEO Brian Thompson in 2024, the national conversation it sparked, and what it revealed about the growing tension between healthcare corporations and the patients they serve. This is a story about scale, innovation, power, controversy, and the future of healthcare itself. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #UnitedHealthcare #UnitedHealthGroup #Optum #Healthcare #HealthInsurance #MedicareAdvantage #HealthcareInnovation #HealthcareBusiness #Biotech #Pharma #HealthTech #BrianThompson #CorporateStrategy #PetriDishPerspectives #HealthcarePolicy #DigitalHealth #ValueBasedCare #ManagedCare #HealthcareEconomics #BusinessPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| May 2026: Biotech & Pharma NEWS Roundup | 01 Jun 2026 | 00:11:20 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure the next generation of oncology, metabolic, and infectious disease assets. From high-stakes acquisitions aimed at building comprehensive "acute care" architectures to massive investments in generative AI-driven discovery engines, the industry has clearly shifted toward a model of integrated precision, prioritizing both the speed of research and the consolidation of complex manufacturing infrastructure. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 57: 23andMe | 28 May 2026 | 00:25:52 | |
This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes. From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe built a direct-to-consumer model that reshaped public engagement with DNA. We break down the science behind SNP genotyping, the shift from ancestry testing to drug discovery partnerships with pharma giants like GSK, and the promise and limits of consumer-driven precision medicine. We also dive into the SPAC-era hype cycle, regulatory and FDA battles, privacy controversies around genetic data ownership, and the deeper ethical question at the heart of the company: who actually owns your biology once it’s been digitized? This is a story about genetics, identity, data, and the uneasy intersection of science and consumer tech. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #23andMe #Genetics #Biotech #DNA #Genomics #PrecisionMedicine #HealthcareInnovation #BioTech #Pharma #DataPrivacy #ConsumerGenomics #SPAC #DrugDiscovery #SciencePodcast #PetriDishPerspectives #Ancestry #DigitalHealth © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 56: Thermo Fisher | 21 May 2026 | 00:23:22 | |
This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufacturing, and the “picks-and-shovels” strategy behind biotech’s biggest breakthroughs. We also unpack the company’s role during COVID-19, its expansion into CDMO services, and why some of the most powerful companies in healthcare are often the ones nobody talks about. This is the story of the invisible engine behind modern biology and the company behind the companies. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #ThermoFisher #Biotech #LifeSciences #Biotechnology #Pharma #DrugDevelopment #Genomics #Diagnostics #CDMO #HealthcareInnovation #PrecisionMedicine #Science #Biopharma #PetriDishPerspectives #LaboratoryScience #SyntheticBiology #ThermoFisherScientific © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 55: Alnylam | 14 May 2026 | 00:23:36 | |
From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine. We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine. This is the story of persistence, platform biology, and the rise of RNA therapeutics. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 54: All about 340B | 07 May 2026 | 00:16:37 | |
In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients. But over time, it has evolved into something much bigger. We unpack how the program actually works, why it’s become a financial cornerstone for many hospital systems, and the growing tension with pharmaceutical companies like Pfizer and Johnson & Johnson. From contract pharmacy battles to questions around transparency and patient benefit, the 340B ecosystem sits at the center of one of the most complex, and controversial, debates in healthcare economics. Because 340B isn’t just about drug discounts. It’s about who captures value in the healthcare system and who it’s really meant to serve. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #340B #HealthcarePolicy #Pharma #DrugPricing #HealthEconomics #Biotech #HealthcareInnovation #PetriDishPerspectives #USHealthcare #PolicyExplained © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| April 2026: Biotech & Pharma NEWS Roundup | 01 May 2026 | 00:11:03 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026! This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 53: CAR-T Therapies | 30 Apr 2026 | 00:25:01 | |
What if cancer treatment wasn’t a drug but a living, evolving system inside your body? In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from treating disease to programming the immune system. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #CAR-T #CellTherapy #Biotech #Oncology #Immunotherapy #CRISPR #HealthcareInnovation #Pharma #BiotechPodcast #PetriDishPerspectives #PrecisionMedicine #CancerResearch #FutureOfMedicine © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 52: Daiichi Sankyo | 23 Apr 2026 | 00:23:05 | |
In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down the rise of Daiichi Sankyo, a company that quietly transformed itself from a cardiovascular powerhouse into one of the most dominant players in modern oncology. This isn’t your typical biotech story. There’s no overnight success, no single “eureka” moment. Instead, we trace a century-long evolution, from the pioneering work of Jokichi Takamine and the early days of enzyme therapeutics, to the merger that unified biological extraction with synthetic chemistry, and ultimately to the company’s bold, high-stakes bet on antibody-drug conjugates (ADCs). At the center of it all is Enhertu, the drug that shattered the traditional HER2 classification and redefined how we think about targeting cancer. We unpack how Daiichi Sankyo solved the ADC “linker problem,” engineered a platform with unmatched precision, and built a pipeline that’s now reshaping treatment across breast, lung, and gastric cancers. We also explore the strategic partnerships with AstraZeneca and Merck & Co., and what they signal about Daiichi Sankyo’s position as a true platform leader in the ADC gold rush. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #DaiichiSankyo #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Enhertu #LifeSciences #BiotechPodcast #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 51: ImmunoGen | 16 Apr 2026 | 00:26:51 | |
In this episode of Petri Dish Perspectives: Biotech Unleashed, we dive into the 40+ year journey of ImmunoGen, a company that refused to give up on one of the most complex and misunderstood technologies in oncology: antibody-drug conjugates (ADCs). From its early days as a Dana-Farber spinout to decades of scientific setbacks, market skepticism, and near-collapse moments, ImmunoGen’s story is anything but linear. We explore how the company survived the “ADC dark ages,” built foundational technology through partnerships with giants like Genentech and Roche, and ultimately made the bold pivot from platform provider to full-fledged drug developer. If you want to understand how long it really takes to build a platform technology, why being early can be both a curse and a competitive advantage, and how persistence shapes success in biotech, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #ImmunoGen #ADC #AntibodyDrugConjugates #Oncology #DrugDevelopment #Pharma #Biotechnology #CancerResearch #AbbVie #LifeSciences #BiotechPodcast #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 50: Exact Sciences | 09 Apr 2026 | 00:23:34 | |
In this episode of Petri Dish Perspectives, we’re dissecting the "Phoenix of Biotech." On March 23, 2026, the era of Exact Sciences as an independent company officially ended with its massive $23 billion acquisition by Abbott Laboratories. But the road to this exit wasn't paved with easy wins, it was forged in the wreckage of a "zombie" penny stock that almost didn't survive 2008. We take you through the high-stakes gamble of the DeeP-C trial, the behavioral economics behind the "Little Blue Box," and the strategic brilliance of the Genomic Health merger. We explore how Kevin Conroy turned a struggling Madison startup into a global diagnostic standard by mastering the one thing most biotechs ignore: the clinical workflow. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives #ExactSciences #AbbottLaboratories #BiotechStrategy #Oncology #Cologuard #LiquidBiopsy #PharmaNews #MAndA #CancerDetection #ScientificTranslator #Diagnostics #HealthTech #KevinConroy #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 49: AI in Pharma / Biotech | 02 Apr 2026 | 00:24:43 | |
In this episode, we explore the high-stakes reality of AI integration in the life sciences. We move past the speculative hype to examine the mechanical necessity of this shift, driven by soaring R&D costs and an explosion of biological data, and how the industry has transitioned from a "serendipity-based" model to one of predictive, generative biology. We break down the leaders of this revolution, comparing the "TechBio" pioneers like Insilico and Recursion with the massive infrastructure bets currently being made by Big Pharma giants. From the rise of autonomous, "closed-loop" labs to significant improvements in target discovery and preclinical timelines, we analyze where the technology is delivering measurable wins and where the "dirty data" gap still holds the industry back. Finally, we address the hard truths of this transition, including the recent wave of industry layoffs and the emergence of the "Scientific Translator" as the most vital role in the modern lab. We look ahead to a 2030 landscape defined by digital control arms and personalized medicine, offering essential lessons for any professional navigating the risks and rewards of an AI-integrated pipeline. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #AI #Pharma #LifeSciences #Podcast #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| March 2026: Biotech & Pharma NEWS Roundup | 01 Apr 2026 | 00:13:27 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for March 2026! This month was dominated by by three massive themes: more AI integrations, M&A deals, and continued GLP-1 challenges. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 48: Ginkgo Bioworks | 26 Mar 2026 | 00:23:44 | |
In this episode of Petri Dish Perspectives, we unpack how Ginkgo Bioworks set out to industrialize biology. From its origins at MIT to building one of the most ambitious synthetic biology platforms in the world, we explore how the company positioned itself not as a traditional biotech, but as a “organism engineering foundry.” We break down Ginkgo’s unique business model, partnering with companies across pharma, agriculture, and consumer goods and how it generates value through cell programming, automation, and massive biological datasets. We also examine the company’s rapid rise, its high-profile SPAC debut, and the intense scrutiny that followed. Along the way, we dive into the science behind synthetic biology, the challenges of scaling engineered organisms, and the big question: can biology truly become an engineering discipline? If you want to understand the future of programmable biology and whether Ginkgo’s platform-first approach can reshape entire industries, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #SyntheticBiology #GinkgoBioworks #Biotechnology #Bioengineering #DrugDevelopment #LifeSciences #Bioeconomy #Startup #SPAC #Innovation #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 47: SUN Pharma | 19 Mar 2026 | 00:24:12 | |
From a small operation built on just ₹10,000 to a global pharmaceutical powerhouse, Sun Pharmaceutical Industries is one of the most compelling growth stories in modern biotech. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how Dilip Shanghvi transformed a niche generics business into one of the largest pharmaceutical companies in the world. We explore Sun Pharma’s early focus on underserved therapeutic areas, its aggressive strategy of acquiring distressed assets, and the pivotal deals that expanded its global footprint, from U.S. market entry to the landmark Ranbaxy acquisition. But this story isn’t just about scale. We also dive into Sun Pharma’s evolution beyond traditional generics into high-margin specialty drugs, including biologics, dermatology treatments, and complex formulations and what that shift means for the future of the company. Along the way, we examine the challenges that shaped Sun’s trajectory, including FDA scrutiny, manufacturing setbacks, and the broader pressures of competing in a race-to-the-bottom generics market. If you want to understand how a company can build a global pharma empire without a single blockbuster discovery and why the future of generics is far more complex than it seems, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Pharma #SunPharma #Generics #DrugDevelopment #Biotechnology #Healthcare #LifeSciences #SpecialtyPharma #BusinessStrategy #EmergingMarkets #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 46: Servier | 12 Mar 2026 | 00:23:15 | |
In this episode of Petri Dish Perspectives, we explore the remarkable history of Servier, France’s largest independent pharmaceutical company and one of the only major drugmakers owned by a non-profit foundation. Founded in 1954 by the physician-pharmacist Jacques Servier, the company grew from a tiny laboratory in Orléans into a global powerhouse in cardiovascular and metabolic medicine. For decades, Servier built its reputation developing treatments for hypertension and diabetes while operating outside the pressures of the public stock market. But the fortress eventually cracked. The company became embroiled in one of the most devastating medical scandals in European history surrounding the drug Mediator (benfluorex). After being marketed for decades as a diabetes treatment, the drug was linked to severe heart valve damage and pulmonary hypertension, triggering a national crisis in France and a landmark trial that reshaped pharmaceutical oversight. Yet Servier’s story does not end with scandal. In the past decade, the company has undergone a dramatic transformation, pivoting billions of euros into oncology research and acquiring cutting-edge therapies targeting rare cancers. From precision leukemia drugs like Tibsovo to the breakthrough brain-tumor therapy Voranigo, Servier is rebuilding itself as a major force in targeted cancer medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 45: BioMarin | 05 Mar 2026 | 00:23:45 | |
Most biotech companies chase massive markets. But BioMarin Pharmaceutical built its entire strategy around something very different: ultra-rare genetic diseases affecting only small patient populations around the world. In this episode of Petri Dish Perspectives: Biotech Unleashed, we break down how BioMarin became one of the most influential rare-disease biotech companies in the industry. We explore the company’s founding vision, the scientific pathways behind its major therapies, and how its team translated academic discoveries into real treatments for patients with conditions that once had no options. We also dive into the discovery and development stories behind BioMarin’s key drugs, from enzyme replacement therapies that defined the early rare-disease model to newer innovations targeting genetic signaling pathways and gene therapy. Along the way, we examine the strategy that allowed BioMarin to build a sustainable biotech business in markets most pharma companies once ignored. If you want to understand how rare disease innovation works and why this niche has become one of the most important sectors in biotech, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #RareDisease #BioMarin #DrugDevelopment #GeneticDiseases #Pharma #Biotechnology #LifeSciences #HealthcareInnovation #GeneTherapy #BiotechPodcast #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| February 2026: Biotech & Pharma NEWS Roundup | 01 Mar 2026 | 00:10:44 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for February 2026! This month was dominated by by three massive themes: The Great IPO Thaw, the "AI Factory" Era, and Regulatory Hardball. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 44: BioNTech | 26 Feb 2026 | 00:25:17 | |
Before the world knew the power of mRNA vaccines, BioNTech was a relatively quiet biotech company focused on one ambitious goal: curing cancer through the immune system. Then the COVID-19 pandemic changed everything. In this episode of Petri Dish Perspectives: Biotech Unleashed, we explore how BioNTech evolved from an academic vision into one of the most important biotechnology companies of the 21st century. We break down the scientific bet on mRNA, the early years building a platform many investors didn’t fully understand, and the pivotal partnership with Pfizer that helped deliver one of the fastest vaccine developments in history. But the story doesn’t stop with COVID. We also examine the criticisms, the people behind the company’s rise, and the next frontier BioNTech is chasing — personalized cancer vaccines and the future of programmable medicine. If you want to understand how a biotech platform can reshape global health and what comes after a once-in-a-generation breakthrough, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #BioNTech #mRNA #Biotechnology #Pharma #DrugDevelopment #COVID19 #Vaccines #BiotechPodcast #LifeSciences #HealthcareInnovation #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 43: ARCH Venture Partners | 19 Feb 2026 | 00:23:46 | |
In this episode of Petri Dish Perspectives, we unpack the strategy and scientific conviction behind ARCH Venture Partners, the venture firm that has quietly helped build some of the most transformative companies in modern biotechnology. From early bets on platform technologies like gene editing and mRNA to backing next-generation leaders such as Juno, Editas Medicine, Beam Therapeutics, and rising metabolic players like Metsera, ARCH has consistently invested at the frontier, long before the science was commercially proven. We explore how ARCH’s concentrated, high-conviction model differs from traditional venture capital, why it prioritizes platform biology over single assets, and how patience, scientific depth, and risk tolerance have allowed the firm to shape entire therapeutic categories. If you want to understand the invisible capital forces behind CRISPR, mRNA, cell therapy, and the obesity drug boom, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #VentureCapital #ARCHVenturePartners #Biopharma #DrugDevelopment #CRISPR #mRNA #SyntheticBiology #HealthcareInnovation #StartupEcosystem #LifeSciences #MetabolicHealth #GeneEditing #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 42: Otsuka | 12 Feb 2026 | 00:23:18 | |
In this episode of Petri Dish Perspectives, we explore the fascinating evolution of Otsuka Holdings, a company that defies traditional pharmaceutical stereotypes. From its origins in Japan as a chemical and nutrition-focused business to becoming a global biopharma innovator, Otsuka has built its reputation by targeting complex and often misunderstood disease areas such as psychiatric disorders, kidney disease, and digital medicine. We unpack the scientific and business journey behind blockbuster therapies like Abilify, examine how Otsuka balanced pharmaceuticals with nutrition and consumer health, and dive into the company’s unique culture of long-term thinking and unconventional innovation. We also explore how Otsuka expanded globally, navigated patent cliffs, embraced partnerships, and positioned itself for the future through digital therapeutics and precision medicine. If you’re interested in how companies succeed by thinking differently and what Otsuka teaches us about patience, diversification, and patient-centered innovation; this is an episode you won’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Pharma #Otsuka #DrugDevelopment #HealthcareInnovation #Biopharma #LifeSciences #PharmaceuticalIndustry #MentalHealthInnovation #DigitalTherapeutics #GlobalPharma #PrecisionMedicine #PetriDishPerspectives #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 41: Gene Therapies | 05 Feb 2026 | 00:25:36 | |
What if medicine could fix disease at its source… by rewriting the genetic code itself? In this episode of Petri Dish Perspectives, we dive into the incredible story of gene therapy, one of the most ambitious and transformative frontiers in modern medicine. From early scientific discoveries about DNA and viral delivery systems, to heartbreaking clinical setbacks that nearly shut the field down, and finally to today’s life-changing treatments for rare diseases, cancer, and genetic disorders, gene therapy represents decades of persistence, innovation, and scientific courage. We explore the researchers who refused to give up, the breakthroughs that revived the field, and the biotech companies leading today’s gene therapy revolution, including pioneers developing CRISPR editing, viral vector platforms, and personalized cellular therapies. We also break down why gene therapy is reshaping the pharmaceutical industry and what the future may hold for curing previously untreatable diseases. If you love biotech, cutting-edge science, and the stories behind medical breakthroughs, this is an episode you don’t want to miss. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #GeneTherapy #Biotech #Genetics #CRISPR #CellTherapy #RareDisease #CancerResearch #Biopharma #MedicalInnovation #PrecisionMedicine #SciencePodcast #LifeSciences #DrugDevelopment #FutureOfMedicine #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| January 2026: Biotech & Pharma NEWS Roundup | 01 Feb 2026 | 00:11:14 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for January 2026! This month was dominated by a surge in Eli Lilly's deals, partnerships, etc. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 40: Eisai | 29 Jan 2026 | 00:23:23 | |
What does it take to spend decades chasing one of medicine’s hardest problems while the rest of the industry walks away? In this episode, we explore the remarkable story of Eisai, the Japanese pharmaceutical company that built its global identity around Alzheimer’s disease. From its founding during World War II and early commitment to ethical medicine, to the blockbuster success of Aricept, and finally the long, controversial road to Leqembi, Eisai’s journey is one of persistence, philosophy, and scientific conviction. We break down how Eisai partnered with Biogen, why leadership under Haruo Naito stayed the course when others exited neuroscience, and how a Japan-based company became a global force in CNS drug development. Along the way, we examine Eisai’s approach to risk, regulation, M&A, and what its future looks like beyond Alzheimer’s. This is a story about long-term thinking in a short-term industry and what happens when belief outlasts doubt. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Eisai #Biotech #Pharma #Alzheimers #Neuroscience #DrugDevelopment #Biogen #HealthcareInnovation #PharmaHistory #LifeSciences #BiotechPodcast #ScienceAndBusiness #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 39: Flagship Pioneering | 22 Jan 2026 | 00:22:57 | |
Flagship Pioneering doesn’t wait for scientific breakthroughs. It builds them. In this episode, we dive deep into the origin story of one of the most influential venture creation firms in biotech and the mind behind it, Noubar Afeyan. From his early life shaped by uncertainty to the founding of a firm that treats biology like an engineering discipline, we explore how Flagship redefined what it means to create companies from first principles. We unpack how Flagship pioneered the venture creation model, its early proximity to the MIT and Harvard ecosystem, and how relationships with the Langer lab helped give rise to Moderna long before mRNA was mainstream. We also examine how Flagship systematically identified entire sectors, from AI-driven protein design to microbiome therapeutics and sustainable agriculture, and why its biggest bets often looked unreasonable for years before paying off. Finally, we look at the people who made their mark, the lessons Flagship teaches about patience and risk in biotech, and what’s next as the firm pushes into AI-native biology and programmable medicine. If you want to understand how the future of life sciences is designed, not discovered, this episode is for you. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #FlagshipPioneering #Biotech #VentureCreation #Moderna #NoubarAfeyan #LifeSciences #Biotechnology #StartupStories #DeepTech #HealthcareInnovation #BioEngineering #AIinBiotech #ScienceToScale © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 38: Biogen | 15 Jan 2026 | 00:24:09 | |
Biogen is one of the most influential and controversial companies in modern biotechnology. Founded in the late 1970s by Nobel-level scientists who believed recombinant DNA would redefine medicine, Biogen helped turn neurology into a commercial field long before most pharma companies dared to enter it. In this episode, we trace Biogen’s full journey, from its academic origins and the rise of interferon therapies for multiple sclerosis, to blockbuster drugs like Avonex and Tysabri. We explore the diseases Biogen chose to fight, why the company doubled down on neurology, and how its scientific culture shaped both its breakthroughs and its blind spots. We then examine Biogen’s high-stakes pivot into Alzheimer’s disease, the controversy surrounding Aduhelm, and the cautious redemption attempt with Leqembi. Along the way, we highlight the people who built Biogen, the alumni who went on to shape the biotech industry, and the hard lessons learned when science, regulation, and patient hope collide. This is a story about ambition, uncertainty, and what it really takes to develop medicines when the biology refuses to cooperate. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biogen #Biotech #Pharma #Neuroscience #Alzheimers #MultipleSclerosis #DrugDevelopment #LifeSciences #Biopharma #HealthcareInnovation #SciencePodcast #BusinessOfBiotech #MedicalResearch #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 37: Theranos | 08 Jan 2026 | 00:26:06 | |
Theranos promised to revolutionize healthcare with a single drop of blood and became one of the most infamous failures in biotech history. In this episode, we trace the full rise and fall of Elizabeth Holmes and Theranos, from its founding in 2003 to its dramatic collapse and criminal convictions nearly two decades later. We explore how ambition, secrecy, and Silicon Valley mythology allowed unproven science to scale into a $9 billion company, how powerful board members and investors failed to ask the right questions, and how whistleblowers and investigative journalism ultimately exposed the truth. This is a story about innovation without evidence, the dangers of charisma over data, and why medicine is uniquely unforgiving of hype. A cautionary tale at the intersection of biotech, venture capital, media, and power. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Theranos #ElizabethHolmes #Biotech #HealthcareInnovation #SiliconValley #MedicalFraud #InvestigativeJournalism #WallStreetJournal #JohnCarreyrou #VentureCapital #HealthTech #ScienceVsHype #BusinessPodcast #BiotechPodcast #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 36: Novo Nordisk | 01 Jan 2026 | 00:23:34 | |
Novo Nordisk’s rise is one of the most extraordinary stories in modern medicine. What began in 1920s Denmark as a response to a fatal disease evolved into a company that reshaped how the world treats diabetes, obesity, and metabolic illness. In this episode, we trace Novo Nordisk’s journey from the discovery of insulin and a decades-long rivalry between two Danish labs, to a landmark merger, global expansion, and steady leadership in diabetes care. We explore how the company mastered insulin manufacturing, pioneered drug delivery systems, and quietly built one of the most disciplined scientific cultures in pharma. This is a story about patience, focus, and how decades of unglamorous excellence can suddenly change the world. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #NovoNordisk #Biotech #Pharma #GLP1 #Ozempic #Wegovy #Diabetes #Obesity #Healthcare #LifeSciences #Biopharma #SciencePodcast #BusinessOfBiotech #MedicalInnovation #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| December 2025: Biotech & Pharma NEWS Roundup | 01 Jan 2026 | 00:10:32 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for December 2025! This month was dominated by a surge in M&A activity and licensing deals. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 35: Dyes to Pharma | 25 Dec 2025 | 00:23:08 | |
Before there were blockbuster drugs, clinical trials, and biotech startups, there was… dye. In this episode of Petri Dish Perspectives, we explore one of the most overlooked origin stories in modern medicine: how 19th-century chemical dye companies laid the foundation for today’s pharmaceutical giants. From coal tar chemistry and synthetic pigments to the birth of industrial drug discovery, this episode unpacks why companies like Bayer, BASF, Ciba, and Hoechst evolved from coloring textiles to curing disease. We dive into the science that connects dyes and drugs, the role of wartime chemistry and national strategy, and the researchers who transformed color into cure. This is the story of how industrial chemistry reshaped medicine and why modern pharma still carries the DNA of its dye-making past. Whether you’re in biotech, pharma, or just curious about how science and history collide, this episode reveals why the pharmaceutical industry didn’t start in hospitals but in chemistry labs. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #PharmaHistory #DrugDiscovery #IndustrialChemistry #Biotechnology #Pharmaceuticals #SciencePodcast #ChemistryToCures #MedicalInnovation #BiotechEducation © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 34: Astellas | 18 Dec 2025 | 00:25:30 | |
In this episode, we explore the evolution of Astellas Pharma, from the merger of two century-old Japanese firms into a global biopharmaceutical powerhouse. We trace how a culture of disciplined research led to breakthrough medicines like Prograf, transformed transplant medicine, and later to Xtandi, a prostate cancer therapy born from academic insight and refined through global collaboration. We unpack how Astellas quietly repositioned itself toward oncology, gene therapy, and regenerative medicine while navigating the challenges of globalization, risk-taking, and long development timelines. This episode is about how long-term thinking, scientific rigor, and cultural continuity can still win in an industry driven by speed. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Astellas #Biotech #Pharma #DrugDiscovery #Oncology #PrecisionMedicine #JapanesePharma #Xtandi #TransplantMedicine #Biopharma #LifeSciences #PharmaStrategy #PetriDishPerspectives © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 33: Novartis | 11 Dec 2025 | 00:23:39 | |
In this episode of Petri Dish Perspectives, we dive deep into the remarkable evolution of Novartis, one of the world’s most influential and scientifically ambitious pharmaceutical companies. From its 18th-century dye-making origins to its modern dominance in gene therapy, oncology, and complex biologics, Novartis has become a case study in strategic reinvention. We explore the company’s defining breakthroughs from Gleevec, the drug that rewrote the playbook for targeted cancer therapies, to cutting-edge innovations like CAR-T, RNA therapeutics, radioligand therapy, and AI-driven drug design. You’ll learn how visionary leaders, bold pipeline bets, and a focus on precision medicine shaped Novartis into a global powerhouse. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Novartis #BiotechPodcast #DrugDiscovery #Gleevec #CAR_T #GeneTherapy #OncologyInnovation #PharmaStrategy #PetriDishPerspectives #HealthcareInnovation #PrecisionMedicine #LifeSciences #BiotechResearch © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| Episode 32: Recursion | 04 Dec 2025 | 00:23:11 | |
Can a machine discover a cure faster than a scientist? Welcome to the revolutionary world of Recursion Pharmaceuticals, the pioneering TechBio company determined to solve biology using AI and industrial automation. In this deep-dive, we explore how Recursion replaced slow, human-biased research with the Recursion OS, a closed-loop platform that generates massive, proprietary biological data. Learn about the company's bold vision, from the crucial $50 million NVIDIA investment and the strategic merger with Exscientia to the immense computational power of the Boltz-2 supercomputer. We analyze their pipeline progress in oncology and rare diseases, discuss the challenges of high cash burn (like the recent pipeline streamlining in November 2025), and examine their critical partnerships with giants like Roche/Genentech. Discover why Recursion is leading the charge to build the digital "Map of Biology and Chemistry" to cut drug discovery time from a decade to mere years. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Recursion #TechBio #AIDrugDiscovery #NVIDIA #Biotech #PharmaInnovation #MachineLearning #OmicsData #Genomics #RecursionOS #PetriDishPerspectives #BiotechPodcast © 2026 The Perspective Bureau LLC. All rights reserved. | |||
| November 2025: Biotech & Pharma NEWS Roundup | 01 Dec 2025 | 00:10:40 | |
Welcome to your essential overview of the global biotech and pharmaceutical landscape for November 2025! This month was dominated by a surge in M&A activity, with high-profile bidding wars! 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews © 2026 The Perspective Bureau LLC. All rights reserved. | |||